Please use this identifier to cite or link to this item: doi:10.22028/D291-41869
Title: Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah's Witness - Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab
Author(s): Cardesa-Salzmann, Teresa Marta
Stephan, Bernhard
Simon, Arne
Furtwängler, Rhoikos
Schöndorf, Dominik
Heine, Sabine
Torfah, Eyad
Lux, Margaux
Meyer, Sonja
Graf, Norbert
Language: English
Title: Clinical Case Reports
Volume: 10
Issue: 5
Publisher/Platform: Wiley
Year of Publication: 2022
Free key words: caplacizumab
immune-mediated TTP – SARS-Cov2
immunoadsorption
Jehovah's Witness
therapy without therapeutic plasma exchange
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: We report the case of a Jehovah's Witness adolescent patient with immunemediated thrombotic thrombocytopenic purpura after SARS-Cov2 infection successfully treated without therapeutic plasma exchange (TPE) using caplacizumab, corticosteroids, rituximab, and extracorporeal immunoadsorption (EIA). Further patientsfor whom TPE is not an option might benefit from this approach.
DOI of the first publication: 10.1002/ccr3.5902
URL of the first publication: https://doi.org/10.1002/ccr3.5902
Link to this record: urn:nbn:de:bsz:291--ds-418698
hdl:20.500.11880/37462
http://dx.doi.org/10.22028/D291-41869
ISSN: 2050-0904
Date of registration: 11-Apr-2024
Faculty: M - Medizinische Fakultät
Department: M - Chirurgie
M - Pädiatrie
Professorship: M - Prof. Dr. Norbert Graf
M - Prof. Dr. Michael Zemlin
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes



This item is licensed under a Creative Commons License Creative Commons